Sign Up
Stories
Biotech Leader Appoints Renowned Director
Share
4D Molecular Therapeutics Raises $300 Mi...
Advancements in Cancer Treatment and Mar...
Advancing ALS Treatment through Protein ...
4DMT Presents Positive Interim Data
Biopharma Innovator GeNeuro Discloses Pr...
Biotech Collaboration Enhances Sector So...
Overview
API
Curative Biotechnology Inc. appoints Dr. Theresa Heah as an independent director and Clinical Development Committee member. Dr. Heah's extensive biomedical experience includes roles at Intergalactic Therapeutics, Kriya Therapeutics, and AsclepiX Therapeutics. The company specializes in innovative treatments for rare diseases, specifically focusing on degenerative eye conditions like Age-Related Macular Degeneration.
Ask a question
How might Dr. Heah's expertise contribute to Curative Biotechnology's research and development efforts?
In what ways does this appointment reflect the broader trend of collaboration between experienced professionals and biotech companies in advancing healthcare?
What impact could the development of a Metformin-based eye drop have on the treatment landscape for Age-Related Macular Degeneration?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Mar 2024
Coverage